Effect of Varma massage with Varma oil and Piratharani kasayam in patients with Adhesive Capsulitis (Frozen Shoulder)

An open labelled double arm non randomized phase II clinical trial, To Compare the effectiveness of Varma Thadaval Murai(Kai Varma Ennai-II-External oil) with Piratharani Kasayam(Internal) in the Management of Kumbavatham(Adhesive Capsulitis) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106033

Enrollment

Registered

2026-03-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M750- Adhesive capsulitis of shoulder

Interventions

Intervention1: Piratharani Kasayam (Internal): Piratharani Kasayam will be administered orally in at a dose of 90 ml twice daily(BD) for 21 days. Intervention2: Varma Thadaval Murai (Kai Varma Ennai-I

Eligibility

Inclusion criteria

Inclusion criteria: 1.Presence of Pain, stiffness and restricted movements in the shoulder joint. 2.Idiopathic cases of adhesive capsulitis. 3.Patients assessed using the SPADI score. 4.History of Diabetes Mellitus. 5.Patients willing to participate and sign the informed consent form. 6.Patients willing to undergo treatment and attend regular follow-up.

Exclusion criteria

Exclusion criteria: 1.History of fracture or surgery of the affected shoulder joint. 2.Autoimmune or inflammatory joint disorders affecting the shoulder. 3.Cardiovascular disease. 4.Tuberculosis or other active systemic infections. 5.Congenital deformities of the shoulder. 6.Pregnant and lactating women. 7.Skin diseases or infection over the affected shoulder region.

Design outcomes

Primary

Measure	Time frame
Change in SPADI(Shoulder Pain and Disability Index) score and shoulder joint range of motion measured by goniometerTimepoint: Baseline and Day 21	—

Secondary

Measure	Time frame
Evaluation of safety and adverse events during the treatment period.Timepoint: Baseline and Day 21	—

Countries

India

Contacts

Public ContactDr R KRISHNAMOORTHI MDS

Government Siddha Medical College and Hospital

drvanamamalai@gmail.com9965606156

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026